Press Release Poster May 30, 2025 Monza (Italy) – Rottapharm Biotech announces that results from the phase I/II study of the EP4 antagonist vorbipiprant (CR6086) with… Read More »Phase I/II study of vorbipiprant combined with anti-PD-1 immunotherapy results in metastatic gastrointestinal non-colorectal cancers presented at ASCO 2025
Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that new exciting preclinical data supporting the advancement of CR10049 (a targeted kinase inhibitor for the inflammatory OA phenotype) have been presented at the Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, held April 24 – 27, 2025 in Incheon, South Korea
Press Release Online Publication December 02, 2024 Monza (Italy) – Rottapharm Biotech announces that results from the phase I/II study of the EP4 antagonist vorbipiprant… Read More »Vorbipiprant combined with PD-1 blockade for refractory microsatellite stable metastatic colorectal cancer phase I/II trial results published in Clinical Cancer Research
Press Release Poster May 31, 2024 Monza (Italy) – Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that… Read More »Updated results and subgroup analysis of the phase I/II study of CR6086 (vorbipiprant) and balstilimab in advanced colorectal cancer presented at ASCO 2024
Press Release Presentation April 11, 2024 Monza (Italy) – Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that… Read More »Rottapharm Biotech announces upcoming oral presentation of CR10049 in the inflammatory osteoarthritis (OA) phenotype at the OARSI World Congress on OA
Press Release Poster October 23, 2023 Monza (Italy) – Rottapharm Biotech announces favourable clinical results of CR6086, its potent and selective small molecule antagonist of the… Read More »Rottapharm Biotech discloses at ESMO 2023 favourable results from the Phase 1/2 study of the EP4 receptor antagonist CR6086 combined with the anti-PD-1 balstilimab in advanced colorectal cancer
Publication January 11, 2023 Takis and Rottapharm Biotech announce the advance publication of the article “A first-in-human trial on the safety and immunogenicity of COVID-eVax,… Read More »COVID-eVax PHASE 1 CLINICAL TRIAL RESULTS PUBLISHED
December 13, 2021 Monza (Italy) – Rottapharm Biotech announces dosing the first patient in the Phase 1/2 study of CR6086 in combination with Agenus’ balstilimab (anti-PD-1)… Read More »Rottapharm Biotech announces the first patient dosed in the Phase 1/2 study of the EP4 receptor antagonist CR6086 combined with Agenus’ anti-PD-1 balstilimab in advanced colorectal cancer
November 29, 2021 Monza and Roma (Italy) – The biotech Takis today announced its strategy to address variant B.1.1.529 (Omicron) and SARS-CoV-2 variants of concern. The… Read More »Takis announces its strategy to generate a vaccine against the Omicron variant (B.1.1.529) of SARS-CoV-2
September 7, 2021 Monza (Italy) – Takis and Rottapharm Biotech today announced preliminary results from the phase I clinical study conducted in Italy with COVID-eVax (the… Read More »Takis and Rottapharm Biotech announce favourable preliminary results from the phase I clinical trial of COVID-eVax, a DNA-based vaccine candidate against COVID-19